RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES
H7537 would require most Rhode Island health insurance policies and health plan contracts to cover scalp cooling systems for individuals diagnosed with cancer who are undergoing chemotherapy. The bill defines scalp cooling systems as FDA-approved medical devices used to cool the scalp before, during, or after chemotherapy in order to prevent or reduce chemotherapy-induced hair loss (alopecia). Coverage would apply to individual and group hospital or medical expense policies, hospital service plans, medical service plans, and health maintenance organization contracts delivered, issued for delivery, or renewed on or after January 1, 2027.
The mandate is written broadly across several chapters of Rhode Island insurance law, including accident and sickness insurance policies, nonprofit hospital service corporations, nonprofit medical service corporations, and HMOs. It also expressly excludes certain limited or specialized coverage types, such as hospital confinement indemnity, disability income, accident-only, long-term care, Medicare supplement, limited benefit health, specified disease indemnity, and other limited benefit policies. The act would take effect upon passage.
The bill would add a new insurance coverage requirement to multiple sections of Title 27, effectively standardizing scalp cooling coverage across major categories of regulated health insurance in Rhode Island. Insurers and health plans subject to the mandate would need to cover an FDA-approved scalp cooling system for eligible cancer patients receiving chemotherapy, beginning with policies renewed or issued on or after January 1, 2027. The measure would not affect the excluded limited-benefit and supplemental policy types listed in the bill.
The available context suggests generally favorable sentiment toward the bill, with the stated purpose focused on reducing a distressing side effect of chemotherapy for cancer patients. The bill’s caption and explanatory note frame the proposal as a patient-support measure rather than a broad insurance overhaul. No committee transcript or vote record is provided, so there is no documented opposition or recorded legislative debate in the supplied materials.
The main potential point of contention is the insurance mandate itself, since requiring coverage can raise concerns about premium impacts, administrative complexity, and whether the treatment should be covered as medically necessary versus elective supportive care. Another possible issue is the bill’s reliance on FDA approval and its application only to chemotherapy patients, which may prompt questions about eligibility, utilization standards, and how insurers will implement coverage. However, no specific objections, amendments, or opposing arguments appear in the provided record.